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The use of large animals as an experimental model for novel treatment techniques has many advantages over the
use of laboratory animals, so veterinary medicine is becoming an increasingly important translational bridge
between preclinical studies and human medicine. The results of preclinical studies show that gene therapy with
therapeutic gene encoding interleukin-12 (IL-12) displays pronounced antitumor effects in various tumor models. A
number of different studies employing this therapeutic plasmid, delivered by either viral or non-viral methods, have
also been undertaken in veterinary oncology. In cats, adenoviral delivery into soft tissue sarcomas has been
employed. In horses, naked plasmid DNA has been delivered by direct intratumoral injection into nodules of
metastatic melanoma. In dogs, various types of tumors have been treated with either local or systemic IL-12
electrogene therapy. The results of these studies show that IL-12 based gene therapy elicits a good antitumor effect
on spontaneously occurring tumors in large animals, while being safe and well tolerated by the animals. Hopefully,
such results will lead to further investigation of this therapy in veterinary medicine and successful translation into
human clinical trials.
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The concept of gene therapy involves the transfer of
genetic material into target cells to overcome a genetic
defect or to provide a protective or corrective function
with the goal of curing a disease or improving the clin-
ical status of a patient [1]. In the case of genetic disease
caused by mutation in a specific gene, the therapeutic ef-
fect of gene therapy is usually achieved by the delivery of
a functional gene into target cells or tissue. Exogenous
gene delivery can also be used as an immune therapy for
the treatment of genetic or non-genetic disorders. The
first human gene therapy trial was conducted in the
USA in 1990 for the treatment of severe immunodefi-
ciency due to adenosine deaminase deficiency [2]. One
year later, the first clinical trial was performed employing
gene therapy in the treatment of cancer (melanoma) [3].
Since then, over 1500 clinical studies have been initiated
for various indications, the majority, over 2/3, in cancer
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reproduction in any medium, provided the orCurrent preclinical and clinical studies employing gene
therapy of cancer show that this treatment approach can
vastly improve the therapeutic outcome of oncologic
patients as either single or adjuvant therapy. Unfortu-
nately, however, the initial human clinical studies
employing gene therapy also revealed important safety
concerns [4,5]. Although laboratory animals have been
invaluable for research of gene therapy, the results of
such studies cannot be directly translated to human
patients. Veterinary medicine is thus becoming an in-
creasingly important translational bridge from in vitro
and preclinical studies to human medicine. Studies on
large animal models can complement research on la-
boratory animals and facilitate more accurate translation
from the preclinical to the clinical level, especially in
studies that are not possible in human patients for vari-
ous reasons.
The use of large animals, mainly dogs, cats, horses and
cattle, as an experimental model for novel treatment
techniques, has many advantages over the use of labora-
tory animals [6]. These species, especially companion
animals, and people share the same living environment
and are therefore subjected to similar environmental risk
factors for the development of certain diseases. They
share many anatomic and physiologic similarities withtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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humans, indicating that comparable genetic mechanisms
are responsible for a particular disease in these species.
Dogs, cats and horses have much longer life spans than
laboratory animals and can therefore naturally reach the
age commonly associated with the highest risk for can-
cer, which makes them especially valuable as natural
models for research in oncology.
Oncologic clinical studies in pets can therefore be per-
formed on spontaneously occurring tumors, which have
different characteristics than experimentally induced
tumors, including inter-individual and intra-tumoral het-
erogeneity, the development of recurrent or resistant
disease, and metastasis to relevant distant sites. Due to
pets’ considerably longer lifespans compared to labora-
tory rodents, possible long-term side effects and other
limitations to novel experimental therapies can be
detected more accurately. All that, in combination with
the lack of established gold-standard veterinary treat-
ment protocols for many diseases, but especially cancer,
provides the opportunity for the early and humane
evaluation of various new therapies, particularly gene
therapy. Experiments on large animal models therefore
provide proof of principle and help discern the potential
efficacy and safety of gene transfer, which cannot be ac-
curately determined on laboratory animals [6,7].
IL-12 based gene therapy
Interleukin-12 (IL-12) was discovered independently by
two different research groups, Trinchieri and colleagues
as a "natural killer-stimulating factor" in 1989 [8] and by
Gately and colleagues in 1990 as a "cytotoxic lymphocyte
maturation factor" [9]. It has been identified as a hetero-
dymeric protein, composed of two subunits, α-chain
with a molecular mass of 35 kDa, also known as p35 or
IL-12α, and β-chain with molecular mass of 40 kDa, also
known as p40 or IL-12 β, which are covalently linked by
a disulfide bridge. Shortly after the discovery of IL-12,
genes for IL-12 in various species were cloned, which
stimulated further investigations relating to the thera-
peutic potential of this newly discovered cytokine [10].
From the beginning, three activities of IL-12 were
already recognized: induction of IFN-γ response, amplifi-
cation of NK cell-mediated cytotoxicity and mitogenic
response of T cells [8]. Based on these biological actions,
it was predicted that this cytokine is required for resist-
ance to bacterial and intracellular parasites, as well as
for the establishment of organ-specific autoimmunity
[11] and it was considered that it shows possible thera-
peutic potential for the treatment of diseases that would
favorably respond to its immunomodulatory actions.
With the additional discovery of its anti-angiogenic
effects [12], IL-12 became one of the most promising
cytokines for the treatment of malignant disease.A model of mechanisms involved in the antitumor
effects of IL-12 predicts that IL-12 directly activates cells
of the adaptive (CD4+ and CD8+ T cells) and innate
arms of immunity by helping to prime T cells, increasing
their survival, enhancing T cell and NK cell effector
functions, as well as promoting the induction of INF-γ
secretion. IFN-γ in turn acts directly on cell components
within the tumor, by enhancing the recognition of tumor
cells through MHC class I processing and presentation
and by modifications of the extracellular matrix, which
results in reduced angiogenesis and tumor invasion. The
end result of these actions is delay of tumor growth and,
ultimately, eradication of the tumor [13].
In the first preclinical studies on the antitumor effect-
iveness of IL-12, recombinant IL-12 (rIL-12) protein was
used. Despite showing a significant effect in these stud-
ies, the success was not adequately translated into the
clinical setting. Systemic application of recombinant IL-
12 resulted in unexpected severe toxicity, even at doses
as low as 1 μg/kg/day [14], which proved to be a major
obstacle to further progression of rIL-12 into clinical
practice. The most common adverse effects of rIL-12
therapy include elevated body temperature, headache,
weakness and gastrointestinal toxicity (stomatitis, nausea
and vomiting). Laboratory changes associated with rIL-
12 toxicity include anemia, neutropenia, lymphopenia,
hypoglycemia, thrombocytopenia, hypoalbuminemia and
liver function test abnormalities. In phase II human clin-
ical trials, systemic rIL-12 therapy even resulted in the
death of treated patients [15]. New strategies for intro-
ducing IL-12 were therefore studied, one of them being
delivery of the gene encoding IL-12, instead of applica-
tion of recombinant protein. The gene delivery systems
for IL-12 include various viral vectors, e.g., adeno- [16-
18], pox- [19] or Semliki Forest virus [20], and non-viral
techniques, e.g., transfer of naked plasmid DNA alone
[21], gene gun technique [22], electroporation [23-25]
and other non-viral methods [26].
IL-12 based gene therapy in cats
In cats, most gene therapy trials presently focus on
cancer, mainly fibrosarcoma, but also on neurological
diseases, various inherited diseases (e.g., mucopolisahar-
idosis VI) and heart disease [27-32].
To our knowledge, there is currently only one report
concerning IL-12 based gene therapy in cats, in which
viral vector was used in 13 cats with spontaneous soft
tissue sarcomas, with an additional 16 cats included in
the feasibility study with viral construct expressing green
fluorescent protein alone or in combination with murine
IL-12 [33] (Table 1). Feline soft tissue sarcomas are a
relatively infrequent, but clinically very challenging oc-
currence, with an estimated incidence between 0.5 – 1
per 10,000 cats [34]. Despite a variety of different

































systemic toxicity at high adenoviral doses
high expression of IL-12 in all tumors
IFN-γ intratumoral expression detected
only with high doses side effects
correlated with IFN-γ expression
[33]







i.tu. human 41% mean reduction of tumor size after
single plasmid injection (11/12 treated
tumors)CR after 3 plasmid injections in 1/
12 tumors only short response (regrowth
11/12 tumors) histological change of
treated tumors no side effects
[46]








i.tu. equine regression in tumor size, with mean
volume of treated tumors decreasing to
approximately 80% of baseline value side
effect: local peritumoral oedema of
smaller treated lesions
[48]






i.tu. equine plasmid enters peripheral blood 10
minutes after intratumoral DNA
application and is present up to 36 hours
post injection, with peak concentration
at 30 minutes intratumoral expression of
IFN-γ was detectable in all melanoma
samples with high interindividual
variability
[47]







EGT i.tu. human statistically significant growth delay of
treated tumors CR in all of the treated
tumors systemic release of IL-12 and/or
IFN-γ antitumor effect on distant
untreated tumors
[66]





EGT i.tu. human 50% median reduction of tumor volumes
(ranging from 15 – 83%) systemic release
of IL-12 and/or IFN-γ change in
histological structure of treated tumors
[56]
7 7 dogs phase I feasibility
and safety study
N/A EGT i.m. human systemic release of IL-12 (1/6 dogs)
induction of IFN-γ response (3/6 dogs)
no detectable side effects
[76]






EGT i.m. human systemic release of IL-12 and/or IFN/γ in
4/6 animals prolongation of patients' life
[65]





ECGT (IL12 + BLM) i.tu. N/A report on eradication of two tumors (the
same two patients are also presented in
the study under no. 10)
[72]










i.tu. feline CR 3/6 dogs
PR 3/6 dogs
[57]
Ref: reference; GFP: green fluorescent protein; mIL-12: murine IL-12; fIL-12: feline IL-12; EGT: electrogene therapy; ECGT: electrochemogene therapy;
i.tu. intratumoral; i.m.: intramuscular; BLM: bleomicyn; CR: complete response; PR: partial response.
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treatment of this disease, the prognosis of affected cats
is poor, with reported recurrence rates from 40 to 70%,
even with a multimodality approach, combining surgery,
radiotherapy and chemotherapy [35,36]. New therapeutic
approaches for the treatment of feline soft tissue sar-
coma are therefore being investigated, including genetherapy, in which mainly IL-2 has been used, delivered
using magnetofection [37], xenogeneic cells [38] or pox-
viral vector [39]. In addition to IL-2, therapeutic genes
encoding GM-CSF [27,37] and IFN-γ [37] and viral sui-
cide gene therapy [40] have also been used.
Siddiqui and colleagues performed a phase I dose es-
calation study using adenoviral vector with feline IL-12
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therapy to fractionated radiotherapy [33]. The cats
underwent 16 fractions of radiation therapy over 22
days, followed by gene therapy performed as intratu-
moral injection of viral vector 3–5 days after completion
of the radiotherapy protocol. Three cohorts of cats were
studied at dose levels of 109, 1010 and 4 × 1010 pfu of
adenovirus per tumor. Twenty-four hours later, treated
tumor nodules were heated to approximately 40–44°C,
which allowed spatial and temporal control of IL-12
expression.
Since this study was designed as a phase I study, the
main focus was on establishing the maximum safe dose
of the viral construct and the detection of possible side
effects in the light of well recognized side effects of
adenoviral gene therapy (immunogenicity) and IL-12
therapy. No treatment-related mortality was seen, al-
though serious side effects were detected in the cats that
received the highest dose of viral construct. These
included lack of appetite, lethargy, pulmonary edema
and hepatic and hematologic toxicities, which even
required intensive care support for up to 2 weeks. IL-12
and IFN-γ mRNA levels were measured using RT-PCR
in the treated tumors 24–48 hours after the induction of
hyperthermia, revealing a consistently high IL-12 mRNA
relative fold increase over the baseline in all tumor sam-
ples taken at the 24-hour time point. A significant in-
crease of IFN-γ mRNA was detected in only 5/13 cats
(mainly in the group receiving the highest dose of viral
vector) and the magnitude of the relative fold increase
was much lower compared to IL-12. Cats in which high
levels of IFN-γ were detected showed clinical signs of
systemic toxicity. Since IFN-γ has been implicated as the
cytokine directly responsible for IL-12 toxicity [15,41], it
can be postulated that, in these cats, locally produced
IL-12 induced an IFN-γ response, resulting in systemic
shedding of IFN-γ, leading to systemic toxicity.
IL-12 based gene therapy in horses
The horse is most commonly used as a large animal
model for osteoarthritis and melanoma, which features
similar histologic and immunohistologic characteristics
as melanoma in humans [42]. Grey horses develop meta-
static melanoma spontaneously and are especially suit-
able as a large animal model for melanoma since a
genetic predisposition for this disease is recognized [43]
and distant metastases occur spontaneously to similar
organs as in the human disease. Conventional oncologic
therapies, such as surgery, cryosurgery or local chemo-
therapy, have only a limited antitumor effect [44]. In
horses, gene therapy of this disease has been attempted
employing suicide gene therapy [45] or therapeutic genes
encoding IL-12 and IL-18 [46-48].As an alternative treatment modality to the conven-
tional therapeutic approach, several studies have used
direct intratumoral injection of IL-12 plasmid without
any additional physical or chemical delivery method [46-
48] (Table 1). Various publications have described differ-
ent aspects of such therapy in altogether 22 grey horses
with multiple tumor nodules. In the first study [46],
plasmid encoding human IL-12 was used, injected intra-
tumorally one to four times in altogether 12 nodules in
7 horses. This therapy resulted in tumor regression, with
a 41% mean reduction of tumor size after a single plas-
mid injection and in one nodule a complete response
was even achieved with three consecutive plasmid injec-
tions. The lowest tumor volumes were seen from day 10
onward until day 99 after therapy and, after reaching the
smallest volume, tumor nodules slowly regrew. The local
response to the therapy was therefore only short term,
but the tumors responded again to repetition of the
therapy, which leads to the conclusion that repetitive
applications of intralesional IL-12 gene therapy at 30-
days intervals would be needed to achieve a more pro-
nounced clinical effect. Local response to the therapy
was also confirmed with histological evaluation of the
treated tumors, which revealed significant peritumoral
infiltration with both CD4+ and CD8+ lymphocytes,
which was not observed in untreated tumors. However,
the therapy did not result in systemic shedding of the
transgene product in the treated animals, since no de-
tectable concentrations of human IL-12 were found in
blood samples taken at different time points from one to
30 days after plasmid injection. Results of this study
proving safety and efficacy also provided basis for a sub-
sequent human clinical phase I study using the same
treatment approach in late-stage malignant melanoma
patients [49].
A decade later, the same research group performed an-
other comprehensive study of the pharmacokinetics and
antitumor effects of intratumoral injection of IL-12 in
metastatic melanoma in grey horses, using equine in-
stead of human IL-12 construct [47]. A thorough evalu-
ation of the pharmacokinetics was performed on 7
horses, in which multiple blood samples and biopsies at
the site of injection were taken at 13 time points imme-
diately before and up to 14 days after intratumoral plas-
mid injection. Plasmid DNA and mRNA was isolated
from the blood samples and quantified using the RT-
PCR method. It was established that plasmid entered the
peripheral blood as soon as 10 minutes after intratu-
moral DNA application and was present up to 36 hours
post injection, with a peak concentration at 30 minutes
and an exponential decrease thereafter. Intratumoral
expression of IFN-γ was detectable in all melanoma
samples, with high inter-individual variability. IFN-γ
expression decreased with time, but much more slowly
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ipheral blood, with IFN-γ remaining significantly ele-
vated above the baseline value at the time of the last
sampling (i.e., 14 days after intratumoral injection of the
plasmid).
The antitumor effect of the same therapeutic plasmid
was evaluated in a double-blind placebo-controlled study
on 8 horses with 22 melanoma nodules [48]. Each tumor
was injected with a cumulative dose of approximately
1.5 mg of equine IL-12 plasmid, divided into 6 consecu-
tive applications. IL-12 gene therapy elicited regression
in tumor size, with the mean volume of treated tumors
decreasing to approximately 80% of the baseline value.
Histologic examination of biopsies in a smaller number
of treated horses revealed similar changes as in the earl-
ier study, i.e., intra- or peritumoral mild perivascular
lymphocytic infiltrations.
The safety aspect of IL-12 gene therapy was
addressed in all three studies on grey horses, with
regular clinical examinations of the treated animals, as
well as hematologic and biochemical examinations of
blood. Side effects included only local peritumoral
oedema of smaller treated lesions (< 1 cm in diameter),
which lasted from 1 to 3 days after plasmid injection.
No systemic side effects were detected, revealed either
as a change in the clinical status of animals or labora-
tory abnormalities, indicating that such a therapeutic
approach can be considered an effective as well as safe
procedure in grey horses, with only minimal transient
local side effects.
IL-12 based gene therapy in dogs
The most commonly used large animal in gene therapy
research is the dog. An important advantage of the use
of dogs compared to laboratory rodents or other pet ani-
mals is the similarity of canine and human immune sys-
tems [50]. Furthermore, successful sequencing of the
canine genome [51] has led to characterization of a var-
iety of genetic disorders in dogs, such as hemophilia,
mucopolisaharidosis VII, and various cardiovascular dis-
eases and cancers. A number of clinical studies have also
been initiated for the treatment of canine cancers, using
different therapeutic genes, such as Fas ligand, bacterial
superantigens and cytokines, including GM-CFS, IL-2
and IL-12 [52-58]. Another palliative approach to
tumor-bearing dogs employed gene therapy with gene
encoding growth hormone releasing hormone in order
to ameliorate tumor cachexia and improve the general
clinical status of patients [59].
The majority of IL-12 gene therapy studies in large
animals have been performed on dogs, all of them util-
izing electrogene therapy of various types of tumors,
either as a single therapeutic approach or as adjuvant
therapy to other treatment methods (Table 1). Electrogenetherapy (EGT) is a procedure in which electroporation is
used for the delivery of various therapeutic genes into tar-
get tissue. Electroporation, i.e., increasing the permeability
of the cell membrane using the application of controlled
electric pulses, has been used as a physical method for
increased intracellular delivery of a range of different
molecules since the beginning of the 1980s [60].
Electroporation-based gene delivery has been used in vivo
since the beginning of the 1990s [61,62] and in the last
quarter of the century, transgenic DNA was successfully
introduced in a vast number of different tissues in a var-
iety of different species [63].
The antitumor effectiveness of IL-12 EGT has
already been established in a number of different ex-
perimental tumor models, including melanoma, lym-
phoma, different carcinomas and sarcoma [64]. The
most pronounced effect of such therapy was growth
delay or even complete long-term eradication of trea-
ted tumors. Furthermore, it generated long-term resist-
ance to the development of new tumors, reduced the
number of lung metastases and consequently pro-
longed the life of the treated animals compared to
control groups [64].
Based on the results of preclinical studies, the first
human clinical study using intratumoral IL-12 EGT on
24 patients with cutaneous metastatic melanoma was
performed [65]. Three EGT procedures were performed
on days 1, 5 and 8, resulting in a good local clinical re-
sponse of the treated tumors, along with a systemic anti-
tumor effect on untreated distant nodules in 53% of
patients.
Intratumoral IL-12 EGT in dogs
In dogs, IL-12 EGT has been investigated on a number
of different induced and spontaneously occurring tumors
[57,58,66,67]. In these studies, either human or feline IL-
12 was used as a therapeutic gene due to the non-
availability of canine IL-12 and high homology between
canine and these two cytokines [68]. Based on amino
acid sequence analysis, canine IL-12 shares an approxi-
mately 90% genetic identity with both human and feline
IL-12. Furthermore, these two types of IL-12 activate the
proliferation of canine peripheral blood mononuclear
cells (PBMC) in vitro and trigger a number of immune
responses in canine PBMC [58,69], which has led to
speculation that they also have an in vivo biologic effect
in dogs. This assumption was confirmed for both cyto-
kines, based on the fact that they displayed a good anti-
tumor effect in various canine tumors, eliciting similar
biologic changes in tumors as in in vitro and preclinical
studies.
Chuang and colleagues employed IL-12 EGT in the
treatment of experimentally transplanted transmissible
venereal tumors (TVT) in 6 experimental beagle dogs
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of 108 canine TVT cells, which originate from spontan-
eous TVT tumor [70] at 8 sites on the back and treated
when the diameter of the tumors reached 1–2 cm. One
mg of plasmid DNA was injected intratumorally into 16
nodules, followed by electroporation. This treatment
showed remarkable antitumor efficacy, with significant
growth delay in all treated tumors, achieving long-term
complete regression, without tumor regrowth in the
one-year observation period. Furthermore, in a dose-
escalating study, even the lowest injected dose (i.e., 0.1
mg of plasmid) elicited significant growth delay in the
treated tumors. IL-12 EGT also had a pronounced sys-
temic effect on distant untreated tumors and induced
long-term resistance to tumor regrowth after re-challenge
with subcutaneous injection of the same tumor cells. Simi-
lar systemic effects have also been shown in experimental
tumor models, e.g., fibrosarcoma [71] and in a human
clinical study [65].
A clinical study in naturally occurring mast cell
tumors in dogs was performed at our institution [57]
(Figure 1). It was conducted on 11 tumor nodules from
8 dogs with intratumoral IL-12 EGT, displaying a good
local antitumor effect and systemic release of transgene
products. The reduction in tumor size was not as pro-
nounced as in experimentally induced TVTs, since no
complete response was achieved, but the size of treated
nodules decreased in the range of 15 – 83% (median
50%) from the initial tumor volume. Additionally, a
change in the histological structure of the treated
tumors was seen, with a reduction in the number ofFigure 1 Intratumoral EGT procedure in a dog with a mast cell tumor
injection of IL-12 plasmid; C: delivery of electric pulses using plate electrod
nodule immediately after the procedure. A marked paleness of the electrop
due to transient reduction of the blood flow to the tissue, caused by occlu
therapy.malignant mast cells and diffuse infiltration of treated
tumors with lymphocytes and plasma cells, as well as de-
granulation of the remaining mast cells. Similar histo-
logical changes are characteristic of plasmid-based IL-12
gene therapy, in which one of the most prominent histo-
logic changes found is intra- and peritumoral lympho-
cytic infiltration [46,48,65,72]. The pivotal role of
lymphocytic infiltration after intratumoral IL-12 EGT
has been demonstrated in preclinical studies, in which
no antitumor effect of such therapy was achieved in
athymic mice deficient in T cells, compared to immuno-
competent mice [71,73]. However, another study pro-
vided evidence to the contrary, since a significant
regression of human melanomas in nude athymic mice
was achieved with repeated intratumoral injections of
IL-12 plasmid, indicating that antitumor effect of IL-12
probably also arises from other modulations of specific
and unspecific immune response mechanisms [74].
An additional two publications have described the im-
plementation of a combination of electrochemotherapy
(ECT) and intratumoral EGT (i.e., electrochemogene
therapy (ECGT)) [58,75] (Figure 2). In ECT, electropor-
ation is used for intracellular delivery of various che-
motherapeutics (mainly bleomycin and cisplatin) for
potentiating the antitumor effect of these drugs [76,77].
Since both ECT and EGT are based on the use of the
same physical phenomenon, they are especially suitable
for combined use. Reed and colleagues [58] combined
intratumoral application of approximately 0.5 IU of
bleomycin and 150 μg of IL-12 plasmid per cm2 of
tumor in 6 dogs with naturally occurring tumors, mainlyin the gluteal region. A: tumor before the procedure; B: intratumoral
es with electric pulse generator CliniporatorW (Igea s.r.l., Italy); D:
orated area compared to the surrounding tissue can be seen (arrow),
sion of blood vessels during electroporation; E: tumor 10 days after
Figure 2 Mast cell tumor on the front leg of a dog, treated with a combination of ECT with cisplatin and IL-12 EGT as part of an
ongoing clinical study at our institution. A: a large ulcerated tumor nodule before therapy, B: one week after the procedure, massive necrosis
of the treated area can be seen; C: one month after the procedure, a cytologically confirmed complete response was achieved.
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high-grade tumors with a statistically poor prognosis
(e.g., histiocytic sarcoma, fibrosarcoma and malignant
melanoma with high mitotic index). A clinical response
to ECGT was observed, with minimal side effects re-
gardless of the tumor type. In three of the 6 treated dogs
(two with oral squamous cell carcinoma and one with
acanthomatous ameloblastoma), a complete response was
achieved and the remaining three (one of each: histiocytic
sarcoma, metastatic melanoma and fibrosarcoma) had a
partial response to treatment. Eradication of the superfi-
cial treated nodules was most probably predominantly
due to previously well described cytoreductive effects of
ECT as the bleomycin and plasmid DNA were injected
together. However the bystander effect on bone lysis re-
pair in invasive tumors could be at least partially
explained by distant effects of IL-12 from the EGT part
of the treatment.
Data on intratumoral cytokine production after local
intratumoral IL-12 EGT is available for preclinical stud-
ies on experimental animals, although the results are
very inconsistent. For example, in experimental melan-
oma models, intratumoral IL-12 EGT produced low con-
centrations of either IL-12 or IFN-γ, with peak levels of
both measured cytokines never exceeding 10 pg/mg of
tumor tissue [72]. On the other hand, significantly
higher concentrations were achieved in IL-12 EGT of a
sarcoma tumor model, with intratumoral cytokine levels
as high as 10 ng/mg of tumor tissue for IFN-γ and 50
ng/mg of tumor tissue for IL-12 [70]. Similar informa-
tion regarding intratumoral concentrations of cytokines
after EGT in larger animals is sparse. Intratumoral cyto-
kine production was measured only in a study on experi-
mentally induced TVTs, in which high peak levels
(approx. 2.5 ng/mg) were reached 7 days after EGT [67].
Such intratumoral cytokine production is not only im-
portant for a direct local antitumor effect of EGT, but
more and more data is presented that sufficient intratu-
moral production of transgene can also result insystemic shedding of encoded product, thus expanding
local therapy to the systemic level [70,78]. Systemic
shedding of therapeutic molecules is most probably a
prerequisite for systemic antitumor effects of gene ther-
apy, for example, the inhibition of growth of untreated
tumors at distant sites, an antimetastatic effect and in-
duction of long-term systemic immunity. However, since
the data on measurement of systemic release of cyto-
kines are scarce, it cannot be ruled out that the systemic
effect can be induced locally. Additionally, the use of
feline and human IL-12 in these studies and modest
availability of commercial tests makes these studies
demanding. Nevertheless, more evidence of systemically
detectable levels of IL-12 and/or IFN-γ in animals trea-
ted with intratumoral IL-12 EGT is needed that would
clarify this point and would lead to better planning of
clinical trials.
Two canine studies featuring intratumoral IL-12 EGT
focused on the detection of systemic release of IL-12
and IFN-γ [57,67]. EGT in both of these studies resulted
in systemic release of IL-12 and induction of an IFN-γ
response, since both cytokines were detected in blood
samples of the treated dogs. In a TVT experimental
model, higher IL-12 concentrations were detected (peak
levels 145 ± 78 pg/ml) compared to spontaneous mast
cell tumors (maximum concentration reached was 12.2
pg/ml). This difference can be explained by much higher
doses of plasmid that were used for treatment of the
TVTs. In both studies, too, induction of an IFN-γ re-
sponse was detected, which further verified the bio-
logical activity of human IL-12 plasmid in dogs, since
one of the most important antitumor actions of IL-12
stems from the induction of IFN-γ production from NK
cells. Interestingly, a similar expansion of local gene
therapy to the systemic level was also detected in an-
other study on dogs with malignant melanoma, which
received an intratumoral injection of lipid-complexed
plasmid DNA encoding a bacterial superantigen and one
of two cytokines, IL-2 or GM-CSF [53]. The therapy led
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the peripheral blood, indicating that local administration
of the vector may have produced a systemic effect.
Intramuscular IL-12 EGT in dogs
An additional two publications have described a slightly
different approach to IL-12 EGT, i.e., intramuscular
IL-12 EGT [66,79]. Our research group performed a
feasibility and safety study on electrotransfection of
IL-12 plasmid into canine skeletal muscle [78]. The main
advantages of using muscle as a target tissue in gene
therapy are the high capacity of protein synthesis and
post-mitotic status of muscle fibers, which enable long-
lasting gene expression, even for more than 1 year [80].
Two different electroporation protocols for efficient
muscle transfection were evaluated in six beagle dogs in
a dose escalation study using plasmid encoding human
IL-12 [78]. Blood samples were collected at different
time points after a single intramuscular plasmid delivery,
for determination of IL-12 and IFN-γ concentrations
and determination of selected haematologic and bio-
chemical parameters. Human IL-12 was detected in the
serum of one dog, which received the highest plasmid
dose (1 mg) and canine IFN-γ above baseline was
detected in three of the six dogs. Hematological and bio-
chemical parameters remained within reference limits
throughout the whole observation period (2 months).
Based on the results of this study, intramuscular IL-12
EGT was employed in tumor-bearing dogs [66]. The
study was performed on a total of six dogs, three of
them with mast cell tumors grade II and III, and the
remaining three with pulmonary histiocytic sarcoma,
osteosarcoma and mammary adenocarcinoma. Each pa-
tient received a single EGT with 1 mg of therapeutic
plasmid. In 4/6 treated patients, serum concentrations of
IL-12 and/or canine IFN-γ were detected in multiple
blood samples (all three dogs with mast cell tumors and
the dog with pulmonary histiocytic sarcoma), showing
that the therapy elicited systemic release of the encoded
transgene and an IFN-γ response. In these four patients,
even though the therapy did not have any effect on the
volume of measurable tumor nodules, surprisingly long
survival times after EGT were achieved, compared to
survival times associated with specific tumor types from
literature review. For example, the patient with pulmon-
ary histiocytic sarcoma survived more than 8 months
after the EGT. According to the literature median sur-
vival time for dogs with this type of tumor, treated with
chemotherapy, is 3 to 4 months [81,82]. However, the
sample size in this preliminary trial was too low and too
heterogenic to make statistically significant conclusions
regarding effect of intramuscular IL-12 EGT on patients'
survival. The results of this study indicate that intramus-
cular IL-12 EGT is a safe procedure in canine cancerpatients, which can result in systemic shedding of IL-12
and possibly trigger an IFN-γ response, which could lead
to prolonged survival of treated animals.
A particularly important finding of all of these canine
studies is that, together with eliciting a good clinical
antitumor effect, IL-12 EGT, applied either intratumo-
rally or intramuscularly, did not cause any significant
side effects in the treated animals. In the light of known
recombinant IL-12 toxicity, the safety aspect of IL-12
EGT was very well addressed in all studies. The toxicity
of IL-12 EGT was specifically evaluated in murine mel-
anoma and squamous cell carcinoma tumor models
[83,84]. The results of the melanoma study [83] showed
that intratumoral EGT did not cause any clinically de-
tectable adverse effects and did not affect laboratory
parameters in the treated animals. The only histologi-
cally noticeable change was focal inflammation and glo-
merulosclerosis of the kidneys at a late time point after
EGT (around 1 month after the procedure), without any
biochemical indicators of diminished kidney function. In
the squamous cell carcinoma model [84], mild, dose
dependent liver toxicity was noticed, detected histologi-
cally and as a transient statistically significant elevation
of alanine aminotrasferase. Furthermore, in the first 7
days after therapy, a trend of decreasing total white
blood cell counts was observed, which returned to nor-
mal values by day 30.
In canine patients, no significant clinical or laboratory
changes were observed in any of the published studies.
The only reported clinically detectable side effect was 48
hour diarrhea in a dog with malignant melanoma [58],
which could not be directly linked to IL-12 EGT and
could be attributed to any number of other causes, since
the patient had a host of other health problems. Other-
wise, dogs tolerated the procedure very well and did not
show any clinical or laboratory indicators of renal, hep-
atic or systemic toxicity or immunosuppression, which
are the most important adverse effects of recombinant
IL-12 therapy [15].
Conclusions
A review of the literature shows that IL-12 based gene
therapy may offer an effective new approach to cancer
therapy in veterinary medicine. With various viral and
non-viral gene delivery methods, a very good local anti-
tumor effect has been achieved in various tumors of
cats, dogs and horses, thus supporting and upgrading
the results of a number of preclinical studies featuring
IL-12 gene therapy. Studies on large animals have
demonstrated that IL-12 based gene therapy is an effect-
ive approach, either as local intratumoral gene transfer
or as systemic treatment through intramuscular thera-
peutic gene delivery, targeting either accessible tumor
nodules or the disseminated disease. It is a safe and
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gene expression, as well as systemic release of the
encoded protein and induction of an IFN-γ response,
making it a promising treatment for large animals with
spontaneously occurring tumors. Such results will hope-
fully lead to further investigation of this therapy in veter-
inary medicine and help in successful translation into
human clinical trials.
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